Thursday, November 30, 2017 11:31:41 AM
Daily SCAM ALERT. Below are the headlines of all of the PR's this company has issued over 4 years claiming cells for trials are being prepared.
Sept. 17, 2013
Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
Nov 4, 2013
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
Dec. 19, 2013
Nuvilex’s Provides Progress Update on Cell Cloning Being Performed by Inno Biologics
April 10, 2014
Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical
Trials in Pancreatic Cancer
28 NOV 17
PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank
Sept. 17, 2013
Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
Nov 4, 2013
Nuvilex Announces Cloning of Cells for Future Phase 3 Clinical Trials Initiated by Inno Biologics
Dec. 19, 2013
Nuvilex’s Provides Progress Update on Cell Cloning Being Performed by Inno Biologics
April 10, 2014
Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical
Trials in Pancreatic Cancer
28 NOV 17
PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
